The content on this site is intended for healthcare professionals only
Dr Rainy Umbas from Jakarta, Indonesia, discusses the ‘Current use of systemic therapies for localised disease’. He explores which treatment modalities are available in Asia, and which factors and specific characteristics should be considered when selecting which treatment modality to use in each individual patient. Dr Umbras reviews the Asia Consensus Statement (Prostate Cancer) recommendations, as well as the European Association of Urology and American Urological Association guidelines. Finally, he considers the pre-operative therapy clinical studies being conducted in localised disease.
This video is sponsored by an educational grant from Janssen Asia Pacific, a pharmaceutical company of Johnson & Johnson
OncoAlert Round Up for September 15-21, 2023
The advantages of IORT for early breast cancer treatment
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival via PSMA-radioguided surgery
Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer
IORT at the Asian Hospital and Medical Center
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients
